Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modeling study

Nana Owusu-Boaitey[1,#], Timothy W. Russell[2], Gideon Meyerowitz-Katz[3], Andrew T. Levin[4,5,6], Daniel Herrera-Esposito[7,8,#,*]

Author affiliations:
1. Case Western Reserve University School of Medicine, Cleveland, USA
2. Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK
3. University of Wollongong, Wollongong, Australia
4. Dartmouth College, Hanover, USA
5. National Bureau for Economic Research, Cambridge, USA
6. Centre for Economic Policy Research, London, United Kingdom
7. University of Pennsylvania, Philadelphia, PA, USA
8. Universidad de la República, Uruguay

# These authors contributed equally to the work
* Corresponding author: dherresp@sas.upenn.edu

Abstract

Background

Serological surveys have been the gold standard to estimate the numbers of SARS-CoV-2 infections, epidemic dynamics, and disease severity throughout the pandemic. Serological assays are known to have decaying sensitivity with time that can strongly bias their results, but there is a lack of guidelines to account for this phenomenon.

Aim

Assess the sensitivity decay of seroassays for detecting infections, its dependence on assay characteristics, and provide a simple tool to correct for this phenomenon.

Methods

We performed a systematic review and meta-analysis of SARS-CoV-2 serology studies. We included studies testing previously diagnosed individuals, without any SARS-CoV-2 vaccines, and excluded studies of cohorts highly unrepresentative of the general population (e.g. hospitalised patients).

Results

Of the 488 screened studies, 76 studies reporting on 50 different seroassays were included in the analysis. Sensitivity decay depends strongly on the antigen and the analytic technique used by the assay, with average sensitivities ranging between 26% and 98% at 6 months after infection, depending on assay characteristics. We find that a third of the included assays depart significantly from manufacturer specifications after 6 months.

Conclusions

Seroassay sensitivity decay depends on assay characteristics, and for some types of assays it can make manufacturer specifications highly unreliable. We provide a tool to correct for this phenomenon, and to assess the risk of decay for a given assay. This can be used to design better serosurveys, and quantify systematic biases in the existing serology literature.

Introduction

Throughout the pandemic, policymakers have been guided by the inferred number of past infections based on serological assays. Seroassays have been heavily used to estimate the proportion of individuals that have been infected by SARS-CoV-2, the rate of fatal or severe SARS-COV-2 infections (1–5); population-wide immunity (6–8); and to anticipate the effect of future infection waves (9,10), among others.

However, antibody levels wane with time after infection (12), reducing the sensitivity of serological assays for detecting previous infections (13–15). We refer to the decay of assay sensitivity with time as seroreversion. Seroreversion is a major potential source of bias when estimating numbers of infections (1,16,17), and because these estimates guide public health policies such as vaccination programs and non-pharmaceutical interventions, it is important to account for this phenomenon. More generally, understanding the limitations of serological testing is important for the management of emerging infectious diseases in general, such as the ongoing monkeypox outbreak, where estimates of exposure to the disease in African populations are based on serological assays with little assessment of the potential for seroreversion (18,19). Strikingly, despite the widespread use of serosurveys and their well known limitations, there is a lack of guidelines to correct for seroreversion in the SARS-CoV-2 literature (17,18).

Time-varying sensitivity of seroassays has been evaluated in previous studies, but these are limited to few assays or short time spans (14,15,21–24). Thus, these studies could not quantify the effect of different assay characteristics on seroreversion, or provide general guidelines to correct for it. Other studies have analysed the variation across time of quantitative antibody levels (12,14,25–29), but while this is informative for other uses of serological assays (e.g. studying antibody or immune protection dynamics), it does not provide a measure of sensitivity for estimating numbers of infections.

In this work we perform a systematic review and meta-analysis of serology studies of COVID-19, to better characterise seroreversion across assays. We collected time-specific sensitivity estimates from serological studies testing previously diagnosed COVID-19

patients who had not received COVID-19 vaccines. We curated the studies to avoid using samples that are highly unrepresentative of the general population (e.g. hospitalised patients). We analysed 76 of over 400 screened studies, encompassing 50 seroassays, 290 data points, and 44992 tests performed.

We present time-varying sensitivity estimates for the assays included in the analysis, and also the average sensitivities of assays with the different characteristics. These group-average sensitivities can be used to approximate the sensitivity of seroassays not included in our sample, providing a general quantitative tool to correct for and assess seroreversion in an assay-specific manne. Finally, we compare time-varying sensitivities to manufacturer reported sensitivities, providing an overview of how seroreversion impacted the performance of emergency-approved seroassays.

Methods

Literature search

We performed a systematic literature review of seroprevalence studies to assess time-dependent sensitivity of seroassays for detecting prior infections. The review included studies identified up to July 13, 2022 using search parameters detailed in a prior publication (30).

We supplemented this analysis with a search on Medrxiv, Biorxiv, PubMed, SSRN, and Google Scholar, on June 30, 2021 using the key "COVID-19 longitudinal, antibody waning" and on February 15, 2022 using the key "COVID-19 seroreversion". Additional studies were taken from a prior review (31). If a study cited prior publications assessing seroreversion in the same research cohort, we included those prior publications.

Inclusion and exclusion criteria for studies to be included in the analysis are listed in the **Supplementary methods**, but the results of the systematic search are summarised in **Figure 1**. A list of the included studies and search details is presented in the GitHub repository associated with the project.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/

Figure 1. Prisma flow diagram. Flow diagram of the considered studies, showing excluded and included studies.

Assay characteristics analysed

Serological assays have different technical characteristics. Some prominent ones are the antigen used, readout technique, antibody isotype, and the design of antibody binding (14,15). We considered only some assay characteristics to keep model complexity low. We did not consider antibody isotype because all assays analysed target some combination of isotypes including IgG, and preliminary did not show differences between these combinations (data not shown). Then, for the readout technique, we considered whether the assay is quantitative or a lateral flow assay (LFA), which are mostly qualitative rapid tests. We did not consider the specific type of quantitative readout technique, guided by preliminary analyses (data not shown). We considered all 3 antigens: nucleocapsid, spike protein, and S1-receptor binding protein (RBD). We also considered 3 different types of antibody binding in quantitative assays: indirect, direct, and competitive.

Statistical model

We fitted a hierarchical logistic regression Bayesian model to the data. We model the likelihood of the number of positive tests x out of N tested individuals (all which have a

previous COVID-19 diagnosis), with a binomial distribution with the sensitivity θ of that data point:

$$P(x|\theta) \propto \theta^x \, (1 - \theta)^{N-x} \qquad (1)$$

Data points are assumed independent, conditional on their sensitivities. We model the sensitivity $\theta_{a,s,t}$ of assay a, at time t, in study s, with the logit function:

$$log\left(\frac{\theta_{a,s,t}}{1-\theta_{a,s,t}}\right) = \left(\mu + u_a + u_s\right) + \left(\beta + b_a\right) \times t \qquad (2)$$

where μ is the mean intercept, u_a and u_s are the effects on the intercept of assay and study, respectively, β is the mean slope, and b_a is the effect of assay on the slope. We set flat priors for μ and β. We set gamma priors with shape and rate parameters of 4 for σ_{ua}, σ_{us} and σ_{ba}.

To study the effect of assay characteristics, we modify equation (2) to include their effects on the slope:

$$log\left(\frac{\theta_{a,s,t}}{1-\theta_{a,s,t}}\right) = \left(\mu + u_a + u_s\right) +$$
$$\left(\beta_{LFA}L_a + \beta_{Direct}D_a + \beta_{Competitive}C_a + \beta_{Nucleocapsid}N_a + \beta_{Spike}S_a + \beta_{RBD}RBD_a + b_a\right) \times t$$

In the equation above, parameters β_{LFA}, β_{Direct} and $\beta_{Competitive}$ are the effects on the slope of using, respectively, LFA, Quantitative-Direct, or Quantitative-Competitive assay designs. Variables L_a, D_a and C_a take values of 0 or 1 to indicate whether assay a uses that design. We note that we do not include a term or a slope for the Quantitative-Indirect assay design, making it the baseline slope (thus, the parameters above indicate a difference relative to this design). Similarly, $\beta_{Nucleocapsid}$, β_{Spike} and β_{RBD} are the effects of the antigen used on the slope.

We fitted the models using STAN (32), with 4 chains with 4000 draws each (1000 warmup) and default parameters.

Model cross-validation

We tested the models using cross-validation, grouping the validation data points so that validation involved extrapolation through time. First we selected an assay to be validated. Then, we separated the assay's data points into those with times earlier, and those with time later than the average time for the assay's data. We then obtained predictions for each of

these two groups, using models fitted leaving out the respective data points. We repeated this procedure for all assays. Further details are described in **Supplementary methods**.

Estimation of testing times

When studies had unknown times between COVID-19 diagnosis and serological testing, we estimated these times. For this, we took the cumulative number of cases C by the median date of the study, and set as the median date of COVID-19 diagnosis as the date in the past with cumulative cases $C/2$. Case numbers were obtained from (33), or from data made available by public health authorities.

Data and code availability

All the data and code needed to reproduce the analysis, the full pointers to the literature sources of the systematic review, and detailed comments about the review process are available at the associated GitHub page
https://github.com/dherrera1911/seroreversion_metaanalysis.

Funding and competing interests
No specific funding or grant was used for this study. Authors declare no competing interests.

Results

Assay variability in seroreversion

First, we fitted a model without considering assay characteristics. In **Figure 2** we see the slope obtained for each assay, with associated uncertainty (see the fitted curves in **Figure S1**). Estimated slopes were highly variable across assays. The random effects of the assay on the slope and the intercept had standard deviation values of, respectively, σ_{ua}=0.26 (95%CrI: 0.19; 0.36) and σ_{ba}=0.66 (95%CrI: 0.31; 1.04). Interestingly, although most assays had decreasing sensitivity as expected (negative slopes), some assays had increasing sensitivities (positive slopes, shaded region in **Figure 2**). Although surprising, previous studies have reported increasing sensitivity for assays of similar characteristics, and have proposed antibody maturation as a cause (14,15) (further analysis in **Figure S2**). There was also considerable variability between studies of a same assay, with a standard deviation of σ_{us}=0.81 (95%CrI: 0.67; 0.97).

We note that while some assays had many data points spanning several months, other assays had only a few time points (**Figure S1**). For the latter, model predictions involve extrapolation through time. We tested our model's performance at extrapolation using a cross-validation procedure specifically designed for this. We found that the predicted 95% credible intervals (CrI) contained the validation data 91.7% of the time (**Figure S1**). For assays with fewer than 9 data points (which comprise 99 of the 286 data points), 95.1% of the data points were within the cross validation CrI.

Assay characteristics determine seroreversion

Next, we analysed the relation between assay characteristics and sensitivity decay. We fitted a new model with effects of different assay characteristics on the assay-specific slope. We included terms for each of the 3 antigens (nucleocapsid, spike, and RBD), and for 3 different assay designs (LFA, Quantitative-Direct, Quantiative-Competitive), leaving the fourth assay design (Quantitative-Indirect) as the baseline slope.

Both the analytic technique and the antigen show important effects on seroreversion (**Figure 3, Table 1**). The slope term for LFA assays was negative β_{LFA}=-0.23 (95%CrI: -0.40;-0.07), and β_{LFA}<0 in 99.6% of the posterior samples, indicating that their sensitivity decays faster than Quantitative-Indirect assays. The slope term for Quantitative-Direct assays had a value of β_{Direct}=0.31 (95%CrI: 0.15;0.48), and β_{Direct}>0 in 99.9% of the posterior samples, indicating that they decay more slowly. The term for Quantitative-Competitive assays had a value of $\beta_{Competitive}$=-0.03 (95%CrI: -0.25;0.20), and $\beta_{Competitive}$>0 in 40.1% of the posterior samples, showing no clear difference with the Quantitative-Indirect assays (which may be due to the few number of assays in this group). Differences between analytic techniques can be appreciated by comparing the different columns of **Figure 3**.

Figure 2. Assay slopes estimated without assay characteristics. Points show the mean of the posterior distribution of the slope for each assay, and horizontal bars show the 95% CrI. The slopes were obtained from the model that does not include effects of assay characteristics, but colour and point shape indicate the characteristics of the assays. The blue rectangle marks assays with slopes significantly greater than 0.

Table 1. Estimated sensitivities (in %) at each time after diagnosis, for each type of assay fitted in the analysis. Each row corresponds to a different type of test, with characteristics indicated in the first 3 columns. Parenthesis show the 95% CrI for each estimate. These estimates do not include the between-assay or between-study variability in their credible intervals. These sensitivities correspond to the red traces and shaded regions in **Figure 3**.

Design	Antigen	Month												
		1	2	3	4	5	6	7	8	9	10	11	12	13
LFA	N	84 (79-89)	75 (66-83)	64 (49-76)	50 (32-69)	37 (19-60)	26 (10-50)	18 (5-41)	12 (2-32)	8 (1-24)	5 (1-18)	3 (0-13)	2 (0-9)	1 (0-6)
LFA	S	87 (83-91)	83 (76-88)	78 (67-86)	71 (57-83)	64 (45-80)	57 (34-77)	49 (24-73)	42 (17-69)	35 (11-65)	29 (7-61)	24 (5-57)	19 (3-53)	16 (2-48)
LFA	RBD	88 (84-91)	85 (78-91)	82 (71-90)	78 (61-89)	73 (51-89)	69 (40-89)	63 (31-88)	58 (22-88)	53 (16-88)	48 (11-87)	44 (7-87)	40 (5-86)	36 (3-86)
Quantitative-Indirect	N	87 (83-91)	83 (77-88)	78 (69-85)	72 (60-82)	65 (50-78)	57 (39-74)	49 (30-70)	42 (22-65)	35 (15-60)	29 (10-55)	23 (7-50)	18 (5-45)	15 (3-40)
Quantitative-Indirect	S	89 (86-92)	88 (84-92)	87 (82-92)	86 (80-91)	85 (77-91)	84 (73-91)	82 (70-92)	81 (65-92)	79 (61-92)	77 (56-92)	76 (51-92)	74 (46-92)	72 (42-92)
Quantitative-Indirect	RBD	90 (87-93)	90 (87-93)	90 (86-94)	90 (84-94)	90 (83-95)	90 (81-95)	90 (79-96)	89 (77-96)	89 (75-97)	89 (72-97)	89 (69-98)	88 (67-98)	88 (64-98)
Quantitative-Direct	N	90 (87-93)	90 (85-94)	90 (84-94)	90 (82-95)	89 (80-95)	89 (77-96)	89 (74-97)	88 (71-97)	88 (68-97)	87 (64-98)	87 (60-98)	86 (56-98)	86 (52-99)
Quantitative-Direct	RBD	93 (90-95)	95 (92-96)	96 (94-98)	97 (95-98)	98 (96-99)	98 (96-99)	99 (97-100)	99 (97-100)	99 (98-100)	99 (98-100)	100 (98-100)	100 (99-100)	100 (99-100)
Quantitative-Competitive	RBD	90 (86-93)	90 (85-93)	89 (82-94)	89 (80-95)	88 (76-95)	88 (73-96)	87 (69-97)	86 (64-97)	86 (59-97)	85 (54-98)	84 (49-98)	83 (44-98)	82 (40-99)

On the effect of antigen, nucleocapsid targeting assays showed faster seroreversion than spike protein ($\beta_{Nucleocapsid} < \beta_{Spike}$ in 99.7% of the posterior samples). Assays targeting RBD had on average slower seroreversion than spike protein, although the effect was not statistically significant ($\beta_{Spike} < \beta_{RBD}$ in 87.3% of the samples). Differences between antigens can be appreciated by comparing the different rows of **Figure 3**. To see how the different slopes translate to differences in seroreversion, the reader can compare the sensitivities of the different types of assays at the same month in **Table 1**. All these results were robust to fitting each assay characteristic separately (**Figures S3, S4**).

The full model had accuracy similar to the original model, with data points falling in the 95% CrI of their predictions 92.0% of the time for the full dataset, and 96.6% for the assays with fewer than 9 data points. However, the full model had more precise predictions, with narrower intervals than the basic model in 81% of the data points.

Figure 3. Sensitivity profiles for different assay characteristics. The sensitivity profile across time for each kind of assay is shown in a different panel. Rows indicate the targeted

antigen (labelled on the left), and columns indicate the analytic technique (labelled on top). For example, the panel in the second row and second column shows assays that target the spike protein (second row label), and that use a Quantitative-Indirect design (second column label). The red lines show the mean sensitivity for each kind of assay. Shaded regions show the 95% CrI of the mean sensitivity of the group (i.e. not accounting for variability between assays). Black lines show the fits for individual assays. Grey dots show the data, with size proportional to the square root of sample size. Empty panels indicate that no assays with those characteristics were found for the analysis.

Reliability of manufacturer reported sensitivities

Finally, we analysed how our estimates of time-varying sensitivity compare to assay specifications provided by manufacturers, the FDA, or the original reporting publication. We found that 4 months after diagnosis, 20% of the assays have sensitivities below 75% of the assay specification. By 6 months after diagnosis, 34% of the assays were below 75%, and 16% of the assays were below 50%. Thus, a few months after a COVID-19 wave, some serological assays can severely underestimate previous infections.

Discussion

Serology based estimates of infections are important to respond to and understand COVID-19. Although it is known that accounting for seroreversion in these estimates is important, there is a lack of appropriate data and guidelines to do so. Few studies correct for seroreversion (1,16,17,20,30,35), and the lack of robust assay-specific estimates of seroreversion make it uncertain how accurate existing adjustments are. In this work, we present the first large-scale systematic analysis of seroreversion across dozens of seroassays for SARS-CoV-2, making three major contributions to help understand seroreversion and establish guidelines to account for it.

First, we provide time-varying sensitivity estimates for 50 assays (**Table S1**), and estimates of the average time-varying sensitivity for different types of assays (**Table 1**, **Figure 3**). These average estimates can be used to approximate time-dependent sensitivity of assays not included in our analysis. This constitutes the first general tool to correct for seroreversion in an assay-specific manner across the SARS-CoV-2 literature. This tool showed good performance at predicting assay sensitivity in a rigorous cross-validation analysis.

Our second contribution is the quantification of how seroreversion depends on assay characteristics (see **Table 1** for a quantification of these effects). We show that seroreversion depends on the antigen targeted by the assay and on its analytical technology (**Figure 3**). On the assay technique axis, assays that use LFA technique (qualitative, rapid tests) show faster sensitivity decay, while quantitative assays with direct antibody binding have the slowest decay. On the antigen axis, assays using nucleocapsid tend to decay faster than assays using spike protein, while assays targeting S1-RBD tend to decay more slowly (although the effect was not significant to the 95% level). These results will allow researchers to assess the risk of seroreversion of serological assays, providing a valuable tool for the design of future serological studies. For example, a strategy to distinguish antibodies derived from the vaccine and from infection is to compare the results of assays targeting S1-RBD and assays targeting the nucleocapsid protein (10,36). Our results suggest that the different seroreversion rates of these types of assays is an important factor to account for in these studies.

Although this is in line with previous reports in the literature (14,15,21), previous studies analysed fewer characteristics in general, and did not quantify their effects. The large differences between assay types observed here outline the importance of assay-specific corrections for seroreversion. For example, while we estimate the average S1-RBD-targeting Quantitative-Direct assays to detect 98% (CrI95%: 96; 99) of prior infections at 6 months, we estimate that the average nucleocapsid-targeting LFA assays detects only 26% (CrI95%: 10;50) (see **Table 1**). These differences may explain some of the more pessimistic estimates of the rate of seroreversion discussed in the literature (35) as being related to the use of LFA assays (37), or nucleocapsid-targeting assays (28) (although see Pérez-Olmeda et al., 2022 for strong seroreversion in an assay without these characteristics).

Our third contribution is the comparison of the sensitivities estimated here to the specifications provided by manufacturers and regulatory organisms. We estimate that a considerable fraction of the assays included in our analysis drop below 75% of their original reported sensitivity by 6 months after diagnosis. This underscores the potential of decaying seroassay sensitivity to bias our epidemiological understanding of COVID-19, and to possibly mislead public health response. This suggests that it is of interest to public health policy makers to ensure that assay manufacturers and regulatory organisms provide information and guidelines regarding seroreversion to researchers.

Our study has some limitations. Although we included more assays than previous studies, many of the included studies counted with data for only a few time points. Also, we were unable to test the effects of important parameters such as the age or the disease severity on seroreversion (14,15,28,38). Furthermore, as we analysed test data conditional on individuals having a previous COVID-19 diagnosis, it is likely that asymptomatic individuals are underrepresented in our sample. Finally, it is not clear how these results would extrapolate to vaccine-induced antibodies, or how these sensitivity estimates change for the different variants of the virus.

In conclusion, this study shows that accounting for seroreversion in serology-based estimates of infection numbers is important for understanding the COVID-19 pandemic, and for the usefulness of the continued use of serological testing to monitor the future effects of COVID-19. These conclusions generalise to other emerging and endemic diseases in which serology is used to characterise epidemiological characteristics and population exposure. We present a novel simple tool for researchers to account for seroreversion when analyzing serological data and when designing serological studies.

References

1. Brazeau NF, Verity R, Jenks S, Fu H, Whittaker C, Winskill P, et al. Estimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modelling. Commun Med. 2022 May 19;2(1):1–13.
2. Herrera-Esposito D, de los Campos G. Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infect Dis. 2022 Mar 29;22(1):311.
3. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID‑19: An overview of systematic evaluations. Eur J Clin Invest [Internet]. 2021 May [cited 2021 Jul 25];51(5). Available from: https://onlinelibrary.wiley.com/doi/10.1111/eci.13554
4. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020 Dec 1;35(12):1123–38.
5. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature [Internet]. 2020

Nov 2 [cited 2020 Nov 5]; Available from:
http://www.nature.com/articles/s41586-020-2918-0

6. Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US
    Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood
    Donations, July 2020-May 2021. JAMA. 2021 Oct 12;326(14):1400–9.

7. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population
    Immunity and Covid-19 Severity with Omicron Variant in South Africa. N Engl J Med.
    2022 Apr 7;386(14):1314–26.

8. Santos-Hövener C, Neuhauser HK, Rosario AS, Busch M, Schlaud M, Hoffmann R, et al.
    Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a
    successfully contained early hotspot (CoMoLo study), Germany, May to June 2020.
    Eurosurveillance. 2020 Nov 26;25(47):2001752.

9. Chapman LAC, Barnard RC, Russell TW, Abbott S, Zandvoort K van, Davies NG, et al.
    Unexposed populations and potential COVID-19 hospitalisations and deaths in
    European countries as per data up to 21 November 2021. Eurosurveillance. 2022 Jan
    6;27(1):2101038.

10. Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, et al. Adapting
    Serosurveys for the SARS-CoV-2 Vaccine Era. Open Forum Infect Dis. 2022 Feb
    1;9(2):ofab632.

11. Lopman BA, Shioda K, Nguyen Q, Beckett SJ, Siegler AJ, Sullivan PS, et al. A
    framework for monitoring population immunity to SARS-CoV-2. Ann Epidemiol. 2021
    Nov 1;63:75–8.

12. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of
    antibody immunity to SARS-CoV-2. Nature. 2021 Mar;591(7851):639–44.

13. Choe PG, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, et al. Antibody Responses 8
    Months after Asymptomatic or Mild SARS-CoV-2 Infection. Emerg Infect Dis. 2021
    Mar;27(3):928–31.

14. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2
    antibody magnitude and detectability are driven by disease severity, timing, and assay.
    Sci Adv. 2021 Jul 30;7(31):eabh3409.

15. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M,
    et al. Antibody response to SARS-CoV-2 for more than one year − kinetics and
    persistence of detection are predominantly determined by avidity progression and test
    design. J Clin Virol. 2022 Jan 1;146:105052.

16. Lohse S, Sternjakob-Marthaler A, Lagemann P, Schöpe J, Rissland J, Seiwert N, et al.
    German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave
    shows importance of long-term antibody test performance. Commun Med. 2022 May

18;2(1):1–12.

17. Shioda K, Lau MSY, Kraay ANM, Nelson KN, Siegler AJ, Sullivan PS, et al. Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies. Epidemiology. 2021 Jul;32(4):518–24.

18. MacNeil A, Abel J, Reynolds MG, Lash R, Fonnie R, Kanneh LD, et al. Serologic evidence of human orthopoxvirus infections in Sierra Leone. BMC Res Notes. 2011 Oct 28;4(1):465.

19. Reynolds MG, Lederman ER, Karem K, Mombouli JV, Moundeli O, Regnery R, et al. Prevalence of Antibodies against Orthopoxviruses among Residents of Likouala Region, Republic of Congo: Evidence for Monkeypox Virus Exposure. Am J Trop Med Hyg. 2007 Dec 1;77(6):1150–6.

20. Karger AB, Brien JD, Christen JM, Dhakal S, Kemp TJ, Klein SL, et al. The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. mSphere. 2022 Jun 15;0(0):e00193-22.

21. McCance K, Wise H, Simpson J, Batchelor B, Hale H, McDonald L, et al. Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting. PLOS ONE. 2022 Mar 31;17(3):e0266086.

22. Bond KA, Williams E, Nicholson S, Lim S, Johnson D, Cox B, et al. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Pathology (Phila). 2021 Oct 1;53(6):773–9.

23. Flower B, Brown JC, Simmons B, Moshe M, Frise R, Penn R, et al. Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. Thorax. 2020 Dec;75(12):1082–8.

24. Perez-Saez J, Zaballa ME, Yerly S, Andrey DO, Meyer B, Eckerle I, et al. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021 Nov 1;27(11):1695.e7-1695.e12.

25. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021 Jun 1;2(6):e240–9.

26. Di Germanio C, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, et al. SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. Transfusion (Paris). 2021;61(9):2677–87.

27. He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. The Lancet. 2021 Mar 20;397(10279):1075–84.

28. Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The

Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. Clin Infect Dis. 2021 Aug 1;73(3):e699–709.

29. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021 Feb 19;12(1):1162.

30. Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health. 2022 May 1;7(5):e008477.

31. Fei Y, Xu H, Zhang X, Musa SS, Zhao S, He D. Seroprevalence and infection attack rate of COVID-19 in Indian cities. Infect Dis Model [Internet]. 2022 Mar 10 [cited 2022 Mar 16]; Available from: https://www.sciencedirect.com/science/article/pii/S2468042722000094

32. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A Probabilistic Programming Language. J Stat Softw. 2017 Jan 11;76(1):1–32.

33. Guidotti E, Ardia D. COVID-19 Data Hub. J Open Source Softw. 2020 Jul 10;5(51):2376.

34. Garritsen A, Scholzen A, van den Nieuwenhof DWA, Smits APF, Datema ES, van Galen LS, et al. Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies. Infect Dis. 2021 Jul 3;53(7):498–512.

35. Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling elderly populations. Eur J Epidemiol. 2022 Mar;37(3):235–49.

36. Stringhini S, Zaballa ME, Pullen N, Perez-Saez J, Mestral C de, Loizeau AJ, et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Eurosurveillance. 2021 Oct 28;26(43):2100830.

37. Herrington DM, Sanders JW, Wierzba TF, Alexander-Miller M, Espeland M, Bertoni AG, et al. Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership. BMC Infect Dis. 2021 Aug 30;21(1):889.

38. Pérez-Olmeda M, Saugar JM, Fernández-García A, Pérez-Gómez B, Pollán M, Avellón A, et al. Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain. J Clin Virol. 2022 Apr 1;149:105130.